Wolverine Asset Management LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Wolverine Asset Management LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 7,800 shares of the biopharmaceutical company’s stock, valued at approximately $3,557,000.

Other hedge funds have also bought and sold shares of the company. Salomon & Ludwin LLC purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $27,000. Atlantic Union Bankshares Corp bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $30,000. ORG Partners LLC raised its stake in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 33 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new stake in Alnylam Pharmaceuticals in the second quarter worth $37,000. Finally, Quent Capital LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $39,000. Institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the subject of several recent analyst reports. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. HC Wainwright set a $570.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 4th. Piper Sandler reiterated an “overweight” rating and issued a $489.00 target price (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Raymond James Financial restated an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday. Finally, Needham & Company LLC increased their target price on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $490.96.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the firm’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total value of $848,055.70. Following the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $7,874,697.12. This trade represents a 9.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 9,577 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the sale, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at $28,452,215.46. This represents a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 56,955 shares of company stock valued at $24,072,733 in the last quarter. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.0%

Alnylam Pharmaceuticals stock opened at $359.27 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company has a market cap of $47.46 billion, a P/E ratio of 1,496.96 and a beta of 0.32. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The business has a 50-day simple moving average of $418.74 and a two-hundred day simple moving average of $421.35.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.